Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop

Lauren T Roland; Timothy L Smith; Rodney J Schlosser; Zachary M Soler; Anju T Peters; Tanya M Laidlaw; Benjamin S Bleier; Vijay Ramakrishnan; Elina Toskala; David W Kennedy; Amber U Luong

doi:10.1002/alr.22633

Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop

Int Forum Allergy Rhinol. 2020 Sep;10(9):1037-1042. doi: 10.1002/alr.22633. Epub 2020 Jul 3.

Authors

Affiliations

¹ Department of Otolaryngology, University of California, San Francisco, CA.
² Department of Otolaryngology, Oregon Health and Science University, Portland, OR.
³ Department of Otolaryngology, Medical University of South Carolina, Charleston, SC.
⁴ Division of Allergy-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL.
⁵ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
⁶ Department of Otolaryngology, Harvard Medical School, Boston, MA.
⁷ Department of Otolaryngology, University of Colorado, Aurora, CO.
⁸ Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA.
⁹ Department of Otolaryngology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
¹⁰ Department of Otolaryngology, Head and Neck Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX.

Abstract

Background: Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness.

Methods: In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients.

Results: The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice.

Conclusion: We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long-term effects of biologics.

Keywords: chronic rhinosinusitis; endoscopic sinus surgery; guideline; medical therapy of chronic rhinosinusitis; topical therapy for chronic rhinosinusitis.

Publication types

Review

MeSH terms

Biological Products* / therapeutic use
Humans
Nasal Polyps* / drug therapy
National Institutes of Health (U.S.)
Rhinitis* / drug therapy
Sinusitis* / drug therapy
United States

Substances

Biological Products

Abstract

Publication types

MeSH terms

Substances

Grants and funding